| Lipids Management |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.9 |
| PCSK9 |
0 |
0.99 |
| LDL Cholesterol |
0 |
0.98 |
| Cardiometabolic Risk Factors |
0 |
0.32 |
| Heart |
0 |
0.29 |
| Lipoproteins |
0 |
0.29 |
| Hospital |
0 |
0.15 |
| Familial Hypercholesterolemia |
0 |
0.1 |
| Mixed Hyperlipidemia |
0 |
0.1 |
| Otolaryngology |
0 |
0.1 |
| Upper Respiratory Tract Infection |
0 |
0.1 |
| Apolipoproteins |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| COVID-19 |
0 |
0.07 |
| Gout |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Hypercholesterolemia |
0 |
0.07 |
| Hyperlipidemia |
0 |
0.07 |
| Hyperuricemia |
0 |
0.07 |
| Liver |
0 |
0.07 |
| Respiratory Tract |
0 |
0.07 |
| Statins |
0 |
0.07 |
| Urinary Tract Infection |
0 |
0.07 |